Finasteride as a Potential Tool to Improve Mesenchymal Stem Cell Transplantation for Myocardial Infarction
January 2012
in “
Medical Hypotheses
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → 
Studysummary This article reviews potential mechanisms by which Finasteride might enhance mesenchymal stem cell viability and differentiation post-transplant, suggesting a supportive role in myocardial infarction therapy, yet reports no clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The article suggests that Finasteride, a type II 5α-reductase inhibitor, could improve the viability of Mesenchymal stem cells (MSCs) used in cell therapy for myocardial infarction. Finasteride could enhance post-transplanted MSC viability by activating the PI3K/Akt pathway and increasing the facilitation of differentiation of MSCs to cardiomyocyte by reducing DHT levels. The article proposes that pretreating MSCs with Finasteride before administering for myocardial infarction could be a possible means of elevating cell survival.
